|
Daily Medical Update
Venous Thromboembolism Prophylaxis & DOACs
Tuesday, March 3, 2026
|
🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.
|
Circulation (2026) - Practice Guideline
Key Findings
- Risk-stratified pathways identified low-risk PE patients appropriate for early discharge/outpatient treatment, while preserving escalation pathways for intermediate/high-risk disease.
- For hemodynamically stable patients, guideline recommendations favored DOAC-based treatment over VKA pathways in most cases because of comparable efficacy with simpler use and lower intracranial bleeding risk in prior evidence.
📋 Practice Implication: Implement a clinic-hospital transition protocol that documents PE risk class at discharge and defaults eligible low-risk patients to DOAC-first follow-up plans.
|
Expert Opinion on Pharmacotherapy (2025) - Meta-analysis
Key Findings
- Across pooled randomized data, oral anticoagulant monotherapy lowered major bleeding compared with OAC plus single antiplatelet therapy.
- Ischemic outcomes were not meaningfully worse with monotherapy, supporting de-intensification once CAD is clinically stable.
📋 Practice Implication: At routine medication reconciliation, actively stop chronic antiplatelet add-on therapy in stable CAD patients who already require long-term anticoagulation unless a current compelling indication exists.
|
The Journal of Emergency Medicine (2025) - Systematic Review/Meta-analysis
Key Findings
- In AF patients with cancer, DOAC therapy versus warfarin showed no worse thromboembolic prevention across pooled outcomes.
- Major bleeding and intracranial bleeding were reduced with DOAC strategies versus warfarin in pooled analyses.
📋 Practice Implication: When co-managing oncology patients with AF, use DOACs as preferred first-line anticoagulation when renal function, interactions, and affordability are acceptable.
|
Journal of Thrombosis and Thrombolysis (2026) - Meta-analysis of RCTs
Key Findings
- Extended-duration postoperative prophylaxis reduced symptomatic and confirmed VTE events versus shorter prophylaxis courses after major orthopedic procedures.
- The reduction in VTE versus short-course prophylaxis was greatest in higher-risk arthroplasty/hip-fracture groups, with bleeding tradeoffs requiring individualized assessment.
📋 Practice Implication: During post-discharge visits, verify prophylaxis stop dates and close care gaps by extending anticoagulant duration in high-risk orthopedic patients per evidence-based windows.
|
BMC Cardiovascular Disorders (2026) - Meta-analysis
Key Findings
- Rivaroxaban prophylaxis was associated with lower postoperative VTE incidence than enoxaparin in pooled total knee arthroplasty comparisons.
- Oral therapy reduced injection burden, which can improve real-world adherence after discharge compared with injectable regimens.
📋 Practice Implication: For eligible post-TKA patients in ambulatory follow-up, prioritize an oral DOAC prophylaxis plan when adherence to self-injection is likely to be poor.
|
|
Recent high-evidence publications support simplifying anticoagulation in stable CAD, favoring DOAC-centered pathways for many VTE/AF scenarios, and reinforcing risk-stratified prophylaxis decisions after hospitalization and orthopedic surgery. The strongest practice-changing signal is deprescribing unnecessary combination antithrombotic therapy to reduce bleeding without sacrificing thromboembolic protection. In parallel, updated PE guidance and newer comparative data support more standardized outpatient transitions for appropriate low-risk patients.
|
|